Soliant Health Launches 2025 Most Beautiful Hospitals Contest
ATLANTA, GA., May 14, 2025 (GLOBE NEWSWIRE) -- Soliant Health, a leading healthcare and education staffing provider, has officially opened nominations for its prestigious 2025 Most Beautiful Hospitals contest. The program recognizes 20 U.S. hospitals that excel in creating environments where healing flourishes through thoughtful design, compassionate care, and community connection.
From today through June 16, patients, healthcare professionals, and community members nationwide are invited to nominate deserving hospitals. The grand prize winner will receive a $5,000 donation to its foundation, courtesy of Soliant Health.
'True beauty in healthcare extends far beyond architectural aesthetics—it encompasses the entire healing experience,' said David Alexander, CEO of Soliant Health. 'This contest celebrates hospitals that thoughtfully design spaces where patients feel comforted, staff feel inspired, and communities feel proud. We've recognized more than 200 outstanding facilities since starting this program in 2009, and we're excited to discover the most beautiful hospitals for this year.'
The Most Beautiful Hospitals contest recognizes standout hospitals that exemplify what it means to be beautiful inside and out. From state-of-the-art facilities to deeply dedicated staff, the chosen hospitals will reflect the full spectrum of what makes a hospital environment welcoming and restorative.
Following the nomination period ending June 16, public voting will open from June 23 through July 25, allowing communities across America to support their local hospitals. The 20 winning facilities will be announced on August 1, 2025.
To submit a nomination or learn more about previous winners, visit www.soliant.com/most-beautiful-hospital-contest.
About Soliant Health
Soliant is a leader in human capital solutions within the education and healthcare sectors. It operates offices in Atlanta, Tampa, Jacksonville, Houston, San Diego, and Greenville. The company identifies and recruits highly skilled healthcare professionals across a wide range of specialties and connects them with healthcare providers in the education, nursing, and pharmacy segments, primarily on a temporary basis. For more information, visit soliant.com.
CONTACT: Naomi Griffin Soliant 904-380-2186 naomi.griffin@soliant.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Biosimulation Market to Attain USD 18.97 Billion by 2034, Rising at 16.9% CAGR
The global biosimulation market is estimated at USD 4.64 billion in 2025 and is projected to grow to approximately USD 18.97 billion by 2034, expanding at a CAGR of 16.94% over the forecast period. Ottawa, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The global biosimulation market was valued at USD 3.97 billion in 2024 and is projected to reach approximately USD 18.97 billion by 2034, expanding at a CAGR of 16.9%, according to a study published by Towards Healthcare, a sister company of Precedence Research. The growth of the market is driven by the growing technological advancements, along with research and development in the sectors, especially the biopharmaceutical sector, which fuels the growth of the market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the biostimulation market in 2023. Asia-Pacific is anticipated to grow at the fastest rate in the biosimulation market during the forecast period. By product, the software segment dominated the biosimulation market in 2023. By product, the services segment is projected to expand rapidly in the market in the coming years. By application, the drug development segment held a dominant presence in the biosimulation market in 2023. By application, the drug discovery segment is expected to grow fastest in the market By end-use, the pharmaceutical & biotechnology companies led the global biosimulation market in 2023. By end-use, the CRO segment is anticipated to grow with the highest CAGR in the market during the studied years. Market Overview & Potential Biostimulation is a process of stimulating or improving biological activity through the modification of the environment, and encourages the specific processes, like bioremediation, which are used for targeting microbes. Key aspects of biostimulation are the targeted approach, environmental factors, and adaptation and efficiency to enhance specific biological processes. It is also used in cosmetic treatments and procedures for the promotion of collagen and elastin production through procedures like PRP (Platelet-Rich Plasma), microneedling, and certain dermal fillers. What is the Growth Potential Responsible for The Growth of The Biosimulation Market? The growth of the market is driven by the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases, which increases the demand for new and advanced therapies and technologies, fueling the growth of the market. The personalized medicine demand, with increasing awareness about health, increases the growth by optimizing the treatment strategies for individuals according to their needs. The technological advancements, like blood-based biosimulation platforms and integration of AI and machine learning to enhance and increase accessibility, scalability, and computational power, further boost the growth of the market. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Growing Trends Associated with the Biosimulation Market? Rising Research and Development Investments The rising spending on research and development for improved drug discovery and development is a growing trend that supports the growth. Increased Adoption of Cloud-Based Solutions The increased adoption of cloud-based platforms to increase offering accessibility, scalability, and cost-effectiveness fuels the growth of the market. Advancements in AI and Machine Learning The integration of AI and machine learning for advanced and efficient, and improved performance boosts the growth of the market. Government Support for Digital Health Government initiatives and support for digital health help enhance and improve the service, which increases the growth of the market. What Is the Growing Challenge in the Biosimulation Market? The key challenge that hinders the growth of the market is the high initial investment in biostimulation software and services, complexity of biological systems, which limits accessibility and growth. The data accuracy and reliability are also crucial and impact drug development decisions, which lack standardization protocols and data interoperability, hindering the growth of the market. Shortage of skilled professionals in biostimulation slows down the adoption of biosimulation tools, which limits the growth and expansion of the market. Become a valued research partner with us - Regional Analysis How Did North America Dominate the Biosimulation Market in 2023? In 2023, North America led the biosimulation market, driven by the rise in new drug approvals, the presence of major industry players, and technological innovations. The US FDA actively promotes digital health technologies in clinical drug development and has established a 'Framework for the Use of DHTs in Drug and Biological Product Development' to boost awareness through workshops, guidance publications, and internal processes. The region's dominance stems from a strong pharma and biotech sector, technological leadership, and a supportive regulatory setting, especially in the US. Why Did the Asia Pacific Biosimulation Market Grow Significantly in 2023? The Asia Pacific biosimulation market is expanding rapidly due to technological progress, a rising burden of chronic diseases, and increased R&D investments in biopharmaceuticals. The adoption of cloud-based biosimulation platforms and the growth of biologics and biosimilars markets further fuel this expansion. Innovations in biosimulation software are making these tools more accessible, especially for smaller companies. Significant investments in R&D, notably in China and India, alongside the increasing emphasis on biologics and biosimilars more complex to develop are key factors behind this growth. Segmental Insights By Product Which Product Segment Dominated The Biostimulation Market In 2023? The software segment led the biosimulation market in 2023. Biosimulation software helps researchers model and simulate complex biological systems, predict drug behavior, optimize treatment strategies, and cut costs and time. The software provides a comprehensive solution and can be used multiple times during the subscription period. It can be accessed anywhere and anytime by researchers, promoting real-time data analysis. The services segment is expected to grow rapidly in the market over the coming years. Several companies offer biosimulation services to measure various parameters needed during drug development. These services save researchers time and are cost-effective. Organizations and academic institutions lacking biosimulation expertise prefer outsourcing these services. Biosimulation services can be provided in-house or through contracts. By Application How did the drug development Segment dominate the Biostimulation Market In 2023? The drug development segment held a dominant position in the biosimulation market in 2023. Drug development involves screening numerous molecules and assessing the safety and efficacy of drugs. Only a small number of novel drugs gain approval and reach the market. Biosimulation streamlines the process by predicting various drug parameters. The rise in novel drug discovery research and increased R&D investments support the segment's growth. The drug discovery segment is expected to grow the fastest during the forecast period. Growing incidences of acute and chronic disorders, increased research in novel drug discovery, and demand for personalized therapy drive this growth. Biosimulation helps identify potential drug candidates for specific diseases, reducing research time and costs. The rising number of new drug approvals, such as the 104 drugs approved by the Chinese regulatory agency NMPA in 2023 (up from 77 in 2022), supports this trend. By end use Which End Use Segment Dominated The Biostimulation Market In 2023? Pharmaceutical and biotechnology companies led the global biosimulation market in 2023. The growth is driven by the increasing number of drug discovery projects, available capital investments, and more collaborations. Quick and successful product launches strengthen these companies' market positions and increase demand for computer modeling. Adoption of biosimulation boosts productivity and resource efficiency. The CRO segment is expected to have the highest CAGR during the forecast period. Contract research organizations (CROs) provide outsourced research services for the pharmaceutical and biotech industries. The growth of CROs correlates with the rising demand for efficient research services. CROs frequently use biosimulation to design and manage research and clinical trials. The availability of technical expertise and suitable infrastructure supports market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Recent Developments In September 2024, Cellworks Group, Inc. announced positive results from a study involving Cellworks' biosimulation platform to accurately predict overall survival (OS) and chemotherapy benefits in two non-small cell lung cancer patient cohorts, thereby advancing personalized treatment. In July 2024, Certara announced the acquisition of Chemaxon, a cheminformatics software provider, to bolster its drug discovery software portfolio. The acquisition was made to strengthen Certara's position in the drug discovery biosimulation market. In March 2024, Exploristics announced a collaboration with Exonate to optimize the study design for Exonate's upcoming Phase IIb study involving a lead candidate, EXN407, for diabetic eye disease. Biosimulation Market Key Players ANSYS, Inc. Atomwise, Inc. BioSymetrics, Inc. Cadence Cellworks Group, Inc. Certara, Inc. Exonate Exploristics Genedata AG Schrodinger Simulations Plus VeriSim Life Most-Accessed Market Insights from Towards Healthcare The global cell and gene therapy market is valued at USD 21.82 billion in 2024 and is projected to reach USD 187.44 billion by 2034, expanding at a CAGR of 24% during 2024–2034. The AI in healthcare market is anticipated to grow from USD 37.98 billion in 2025 to approximately USD 674.19 billion by 2034, registering a robust CAGR of 37.66% between 2025 and 2034. The U.S. behavioral health market stands at USD 92.2 billion in 2024, is set to grow to USD 96.9 billion in 2025, and is expected to reach USD 151.62 billion by 2034, progressing at a CAGR of 5.1% from 2024 to 2034. The home healthcare market is projected to expand from USD 226.92 billion in 2025 to USD 476.80 billion by 2034, growing at a CAGR of 8.6% during 2025–2034. The U.S. 503B compounding pharmacies market is forecast to increase from USD 1.25 billion in 2025 to USD 2.42 billion by 2034, at a CAGR of 7.63% over the period 2025–2034. The global CAR T-cell therapies market is estimated at USD 6.52 billion in 2024 and is projected to soar to USD 88.51 billion by 2034, advancing at a strong CAGR of 29.8% during 2024–2034. The global child care market is valued at USD 245.10 billion in 2025 and is expected to reach USD 404.46 billion by 2034, growing at a CAGR of 5.72% from 2024 to 2034. The global pharmaceutical CDMO market was valued at USD 146.05 billion in 2023 and is projected to grow to USD 315.08 billion by 2034, expanding at a CAGR of 7.24% between 2024 and 2034. The global basal cell carcinoma treatment market is valued at USD 3.33 billion in 2024, estimated at USD 3.67 billion in 2025, and is projected to reach USD 9.01 billion by 2034, rising at a CAGR of 10.48% from 2025 to 2034. The global smart healthcare market is estimated at USD 283.41 billion in 2024, expected to reach USD 335.85 billion in 2025, and further expand to USD 1,547.41 billion by 2034, at a CAGR of 18.5% during 2024–2034. Segments Covered in The Report By Product Software Services In-house Services Contract Services By Application Drug Development Drug Discovery Others By Delivery Model Subscription Models Ownership Models By End-Use Pharmaceutical & Biotechnology Companies CROs Regulatory Authorities Academic Research Institutions By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramSign in to access your portfolio
Business Upturn
3 hours ago
- Business Upturn
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union (EU) to treat desmoid tumors. 'Desmoid tumors can have a profound impact on people's lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, there have been no approved medicines in Europe,' said Bernd Kasper, M.D., Ph.D., Professor, University of Heidelberg, Mannheim Cancer Center, Mannheim, Germany, and principal investigator of the DeFi trial. 'OGSIVEO is a highly innovative therapy with efficacy data demonstrating both meaningful antitumor activity and a significant improvement in desmoid tumor symptoms, including a significant reduction in pain which is the most debilitating symptom reported by patients.' 'This approval is a long-awaited advance for desmoid tumor patients, their families and physicians in Europe,' said Lynne Hernandez, Executive Director of the Desmoid Tumor Research Foundation. 'It is our hope that patients will benefit from greater awareness of desmoid tumors, faster diagnoses, and better outcomes now that there is an approved treatment.' Desmoid tumors are rare, locally aggressive tumors that form in the connective tissues of the body.1,2 Approximately 1,300 to 2,300 new cases of desmoid tumors are diagnosed annually in the EU.3,4,5 These tumors can cause severe pain, limited function, loss of mobility, disfigurement and fatigue.1,6-10 They are challenging to manage because of their unpredictable nature and high rate of recurrence, which can significantly impact an individual's quality of life.2,7,8,11,12 Desmoid tumor experts and treatment guidelines now recommend medical therapy as first-line intervention instead of surgery for most tumor locations requiring treatment.13,14 'We would like to extend our gratitude to the patients, families, investigators, and advocacy organizations who helped make this EC approval possible,' said Danny Bar-Zohar, MD, CEO of Healthcare and Executive Board Member at Merck KGaA, Darmstadt, Germany. 'OGSIVEO is already established as the standard of care systemic therapy for desmoid tumors in the U.S., and our goal is to bring the same treatment benefits to patients in Europe. Following last month's EC approval of our therapy for patients with NF1-PN, we are in the unique position of launching two innovative treatments — underscoring our commitment to the rare tumor patient community.' The EC approval of OGSIVEO is based on results from the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors and met the primary endpoint of improving progression-free survival (PFS). OGSIVEO demonstrated a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). OGSIVEO also demonstrated a significant improvement in objective response rate (ORR). The confirmed ORR based on RECIST v1.1 was 41% with OGSIVEO versus 8% with placebo (p<0.001); the complete response rate was 7% in the OGSIVEO arm and 0% in the placebo arm. The median time to first response was 5.6 months with OGSIVEO and 11.1 months with placebo. Additionally, OGSIVEO demonstrated early and sustained improvement in patient-reported outcomes (PROs), including pain (p<0.001), desmoid tumor-specific symptoms (p<0.001), physical/role functioning (p<0.001), and overall health-related quality of life (p≤0.01).13 OGSIVEO exhibited a manageable safety and tolerability profile. The most common adverse reactions reported in 88 patients receiving OGSIVEO across all studies (69 patients from DeFi and 19 patients from early phase studies) were diarrhoea (85%), rash (65%), ovarian toxicity in women of childbearing potential (60%) nausea (59%), fatigue (50%), hypophosphataemia (50%), headache (40%) and stomatitis (40%).13 About the DeFi Trial DeFi (NCT03785964) was a global, randomized (1:1), multicenter, double-blind, placebo-controlled pivotal Phase 3 trial that evaluated the efficacy, safety and tolerability of nirogacestat in adult patients with progressing desmoid tumors. The double-blind phase of the study randomized 142 patients (nirogacestat, n=70; placebo n=72) to receive 150 mg of nirogacestat or placebo twice daily. Key eligibility criteria included tumor progression by ≥20% as measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) within 12 months prior to screening. The primary endpoint was progression-free survival, as assessed by blinded independent central review, or death by any cause. Secondary and exploratory endpoints included safety and tolerability measures, objective response rate, duration of response, changes in tumor volume assessed by magnetic resonance imaging (MRI), and changes in patient-reported outcomes. DeFi also included an open-label extension phase. About Desmoid Tumors Desmoid tumors are rare, locally aggressive tumors of the soft tissues that can be serious, debilitating, and, in rare cases when vital structures are impacted, life-threatening.1,2 Desmoid tumors are most commonly diagnosed in patients between the ages of 20 and 44 years, with a two-to-three times higher prevalence in females.3,11 It is estimated that there are 1,300-2,300 new desmoid tumor cases diagnosed per year in the European Union. 3,4,5 Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical resection.11,12 Desmoid tumor experts and treatment guidelines now recommend systemic therapies as first-line intervention for most tumor locations requiring treatment.14,15 About OGSIVEO® (nirogacestat) OGSIVEO® (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor approved in the United States and European Union as monotherapy for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The FDA and the EMA have granted Orphan Drug designation for OGSIVEO for the treatment of desmoid tumors. For the full list of side effects and restrictions with OGSIVEO, see the full Summary of Product Characteristics. IMPORTANT SAFETY INFORMATION Diarrhoea Diarrhoea was reported in patients receiving nirogacestat. Patients who experience diarrhoea during treatment with nirogacestat should be monitored and managed using anti‑diarrhoeal medicinal products. For Grade 3 diarrhoea that persists for ≥ 3 days despite maximal medical therapy, nirogacestat should be withheld until diarrhoea is resolved to Grade ≤ 1 or baseline, then it should be restarted at 100 mg twice daily. Skin and subcutaneous tissue disorders Dermatologic reactions, including maculopapular rash, folliculitis, and hidradenitis, were reported in patients receiving nirogacestat. Patients should be monitored for dermatologic reactions throughout the course of treatment and managed as clinically indicated. For Grade 3 dermatologic reactions, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily. Ovarian toxicity Ovarian toxicity was reported in female patients of childbearing potential receiving nirogacestat. Ovarian toxicity, identified based on abnormal reproductive hormone levels or peri‑menopausal symptoms, was reported in 75% of women of childbearing potential receiving nirogacestat in the DeFi study. Ovarian toxicity has been reported to resolve in 79% of women of childbearing potential during treatment. Follow up information is available for all but two out of 27 patients; after stopping treatment, ovarian toxicity was reported to resolve in all women of childbearing potential for whom data are available. Effects of nirogacestat on human fertility are unknown. Based on findings from animal studies, female fertility may be impaired. Women of childbearing potential should be advised about the risk of ovarian toxicity before initiating treatment with nirogacestat. Patients should be monitored for changes in menstrual cycle regularity or the development of symptoms of oestrogen deficiency, including hot flashes, night sweats, and vaginal dryness. Electrolyte abnormalities Electrolyte abnormalities, including hypophosphataemia and hypokalaemia, were reported in patients receiving nirogacestat. Phosphate and potassium levels should be monitored regularly and supplemented as necessary. For Grade 3 hypophosphataemia persisting for ≥ 7 days despite maximal replacement therapy, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily. For Grade 3 hypokalaemia of any duration, despite maximal replacement therapy, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily. Hepatic abnormalities ALT or AST elevations were reported in patients who received nirogacestat. Liver function tests should be monitored regularly. For ALT or AST ≥ 3 to 5 x ULN, nirogacestat should be withheld until ALT, AST, or both are resolved to < 3 x ULN or baseline, then it should be restarted at a dose of 100 mg twice daily. For ALT or AST > 5 x ULN, nirogacestat should be permanently discontinued (see section 4.2). Non‑melanoma skin cancers Non‑melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) were reported in patients receiving nirogacestat. Skin examinations should be performed prior to initiation of nirogacestat and routinely during treatment with nirogacestat. Cases should be managed according to clinical practices and patients may continue with nirogacestat treatment without dose adjustment. Embryo‑foetal toxicity – Contraception in males and females Nirogacestat may cause foetal harm when administered to a pregnant woman. Patients should be advised of the potential risk to a foetus. Women of childbearing potential must have a negative pregnancy test prior to initiating nirogacestat treatment. Pregnancy testing during treatment with nirogacestat should be considered for women of childbearing potential experiencing amenorrhoea. Women of childbearing potential receiving nirogacestat must use highly effective contraceptive methods during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. Women of childbearing potential should be advised to inform their healthcare provider immediately of a known or suspected pregnancy, and they must stop taking nirogacestat if they become pregnant. Male patients with female partners of childbearing potential should be advised to use highly effective contraceptive methods during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. About SpringWorks Therapeutics SpringWorks Therapeutics, a healthcare company of Merck, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). We are also advancing a portfolio of novel targeted therapy product candidates for patients with additional rare tumors and hematological cancers. For more information, visit and follow @SpringWorksTx on X, LinkedIn, Facebook, Instagram and YouTube. About Merck Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries. Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service. Contacts: Media [email protected] References Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives. Pathologica . 2021;113(2):70-84. doi:10.32074/1591-951X-213. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol . 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374. van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol . 2015;22(9):2817-2823. doi:10.1245/s10434-015-4632-y. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer . 2020;127:96-107. doi:10.1016/ Eurostat. Population structure and ageing. European Commission. Accessed June 12, 2025. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol . 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374. Constantinidou A, Scurr M, Judson I, Litchman C. Clinical presentation of desmoid tumors. In: Litchman C, ed. Desmoid Tumors. Springer; 2012:chap 2. Accessed June 12, 2025. Bektas, M, et al. Desmoid tumors: a comprehensive review. Adv Therapeutics. 2023. Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? Support Care Cancer . 2019;27(3):965-980. doi:10.1007/s00520-018-4386-8. Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer . 2020;126(3):531-539. doi:10.1002/cncr.32555. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc . 2017;92(6):947-964. doi:10.1016/ Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg . 1989;210(6):765-769. doi:10.1097/00000658-198912000-00012. OGSIVEO. EMA. Summary of product characteristics (SmPC). SpringWorks Therapeutics, Inc. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer . 2020;127:96-107. doi:10.1016/ Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 12, 2025. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
